Filtered By:
Specialty: Neurology
Drug: Plavix
Education: Study

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 243 results found since Jan 2013.

Antiplatelets and Anticoagulants in Ischemic Stroke,Transient Ischaemic Attack: A Practice Survey Among Singapore Neurologists
CONCLUSIONS: The widespread use of aspirin for long-term secondary prevention is similar to other countries. The variation in the use of antithrombotic agents in other settings may reflect the lack of sufficient evidence to guide therapy in the various specific stroke patient management scenarios.KEY WORDS: neurologist, practice, antiplatelet, anticoagulant, stroke, cerebrovascular disease.PMID:35470408
Source: Acta Neurologica Taiwanica - April 26, 2022 Category: Neurology Authors: Narayanaswamy Venketasubramanian Source Type: research

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
Conclusions: HPR and clopidogrel resistance were more frequent in recurrent ischemic stroke patients receiving clopidogrel than in those receiving DAPT. Smoking was independently associated with less clopidogrel resistance among those receiving clopidogrel SAPT but not in those receiving DAPT.
Source: Frontiers in Neurology - August 10, 2021 Category: Neurology Source Type: research

Novel Predictors of Future Vascular Events in Post-stroke Patients —A Pilot Study
Conclusions: A combination of NAR reflecting the inflammatory state and AUCupper indicating HTPR may provide a better prediction of recurrent ischemic events suggesting a better selection of patients at risk, thus providing an individually tailored vascular therapy.
Source: Frontiers in Neurology - June 18, 2021 Category: Neurology Source Type: research

Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are administered to acute ischemic stroke patients as secondary prevention. Clopidogrel involves biotransformation by cytochrome P450 (CYP) enzymes into an active metabolite, and single nucleotide polymorphisms (SNPs) can influence the efficacy of this biotransformation. Despite the therapeutic advantages of aspirin, there is significant inter-individual heterogeneity in response to this antiplatelet drug. In this clinical review, the recent advances in the biomarkers of antiplatelet agents in acute ischemic stroke are discussed. The s...
Source: Frontiers in Neurology - June 10, 2021 Category: Neurology Source Type: research

Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome
Antiplatelets agents are widely used and effective for secondary prevention of vascular diseases. Some patients might have reduced platelet inhibition on antiplatelet therapy with a higher risk of ischemic complications.1,2 The role of platelet function monitoring (PFM) has been extensively investigated in cardiology. Resistance to Clopidogrel correlates with higher risk of long-term cardiovascular events and coronary stent thrombosis.3,4 Similarly, studies performed after elective carotid stenting showed that ischemic recurrence and early stent thrombosis are more common in non-responders to Clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - May 5, 2021 Category: Neurology Authors: Ludovico Ciolli, Nicoletta Lelli, Francesca Rosafio, Stefania Maffei, Federico Sacchetti, Laura Vandelli, Maria Luisa Dell'Acqua, Livio Picchetto, Giuseppe Maria Borz ì, Riccardo Ricceri, Roberta Pentore, Manuela Tondelli, Gabriele Vandelli, Noelia Rodrà Source Type: research

Clopidogrel Plus Aspirin in Patients With Different Types of Single Small Subcortical Infarction
Conclusions: There was no significant difference in the efficacy of clopidogrel plus aspirin compared with aspirin alone between patients with SSSI + PAD and SSSI – PAD in the CHANCE trial. Studies in other populations and with adequate power are needed to further verify such findings.
Source: Frontiers in Neurology - March 29, 2021 Category: Neurology Source Type: research

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged le...
Source: BMC Neurology - March 9, 2021 Category: Neurology Authors: Changqing Li, Weihua Jia, Jian Li, Fangfei Li, Jing Ma and Lichun Zhou Tags: Research article Source Type: research

Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review
The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that ti...
Source: Frontiers in Neurology - February 25, 2021 Category: Neurology Source Type: research

Pre-treatment of Single and Double Antiplatelet and Anticoagulant With Intravenous Thrombolysis for Older Adults With Acute Ischemic Stroke: The TTT-AIS Experience
Conclusion: For older adults with higher baseline severity of acute ischemic stroke, DAPP may increase the risk of SICH and mortality post IVT. However, DAPP is still not an indication to withdraw IVT and to prescribe low-dose IVT for older adults.
Source: Frontiers in Neurology - February 22, 2021 Category: Neurology Source Type: research

CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy
This study measures effect ofCYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability ofCYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time<1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or ...
Source: Translational Stroke Research - February 21, 2021 Category: Neurology Source Type: research

Association between insulin resistance and aspirin or clopidogrel resistance in Chinese patients with recent ischemic stroke/TIA.
Conclusions: Insulin resistance was an independent predictor for development of antiplatelet drug resistance in patients with recent minor ischemic stroke or TIA. More attention should be paid to recognize these patients and antithrombotic effect should be monitored when antiplatelet drugs were applied to these patients. PMID: 33455562 [PubMed - as supplied by publisher]
Source: Neurological Research - January 21, 2021 Category: Neurology Tags: Neurol Res Source Type: research

Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke.
Authors: Qiu T, Li C, Huang L, Xiao H, Deng X, Dai X, Fu S, Wang J, Gong Q, Luo Q, Wang M, He W, Chen M Abstract Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS. A total of 98 patients with mild to moderate AIS randomly were divided into 2 groups within 48 h: the treatment group treated with tirofiban and, and the control group treated with aspirin + clopidogrel. The treatment group was given the same scheme as the control group after the treatment of tirofiban co...
Source: Neurological Research - December 6, 2020 Category: Neurology Tags: Neurol Res Source Type: research

CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease
Intracranial atherosclerotic disease (ICAD) is responsible for 8-10% of acute ischemic strokes, and resistance to antiplatelet therapy is prevalent. CYP2C19 gene loss-of-function (up to 45% of patients) causes clopidogrel resistance. For patients with asymptomatic ICAD and ICAD characterized by transient ischemic attack (TIA), this study measures the effect of CYP2C19 loss-of-function on ischemic stroke risk during clopidogrel therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - November 24, 2020 Category: Neurology Authors: Pious D. Patel, Praveen Vimalathas, Xinnan Niu, Chevis N. Shannon, Joshua C. Denny, Josh F. Peterson, Rohan V. Chitale, Matthew R. Fusco Source Type: research

Hybrid Recanalization for the Treatment of Carotid/Vertebral In-stent Restenosis or Occlusion: Pilot Surgery Experiences From One Single Center
Conclusion : The hybrid technique maybe a safe and feasible treatment option to recanalize in-stent restenosis or occlusion with acceptable complications.
Source: Frontiers in Neurology - November 24, 2020 Category: Neurology Source Type: research